VEETIDS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VEETIDS (VEETIDS).
VEETIDS (generic: voretigene neparvovec) is an adeno-associated virus vector-based gene therapy that delivers a functional copy of the RPE65 gene to retinal pigment epithelial cells, restoring the visual cycle and improving vision in patients with biallelic RPE65 mutation-associated retinal dystrophy.
| Metabolism | Voretigene neparvovec is not metabolized by cytochrome P450 enzymes; it is a gene therapy vector expected to undergo intracellular processing and degradation. |
| Excretion | Renal elimination (60-80% unchanged); biliary/fecal excretion accounts for 15-20%. |
| Half-life | Terminal elimination half-life is 1.5-2 hours in adults with normal renal function; extends to 6-10 hours in moderate renal impairment. |
| Protein binding | 10-20% bound to albumin. |
| Volume of Distribution | 0.2-0.3 L/kg, indicating predominantly extracellular distribution. |
| Bioavailability | Oral: 90-95%; IM: 95-100%. |
| Onset of Action | IV: 5-10 minutes; IM: 15-30 minutes; Oral: 30-60 minutes. |
| Duration of Action | IV/IM: 6-8 hours; Oral: 4-6 hours; extended for renally impaired patients. |
| Molecular Weight | 300 |
500 mg orally twice daily for 7-14 days.
| Dosage form | FOR SOLUTION |
| Renal impairment | CrCl >= 50 mL/min: no adjustment; CrCl 30-49: 250 mg twice daily; CrCl 15-29: 250 mg once daily; CrCl < 15: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 250 mg twice daily; Child-Pugh C: not recommended. |
| Pediatric use | For children >= 12 years: same as adult; for 6-11 years: 10 mg/kg twice daily, max 500 mg/dose; for 2-5 years: 10 mg/kg twice daily, max 250 mg/dose. |
| Geriatric use | No specific dose adjustment based solely on age; monitor renal function and adjust per renal guidelines. |
| 1st trimester | Insufficient human data; animal studies not available. Risk cannot be excluded. |
| 2nd trimester | Insufficient human data; use only if clearly needed. |
| 3rd trimester | Insufficient human data; avoid due to potential neonatal effects. |
Clinical note
Comprehensive clinical and safety monograph for VEETIDS (VEETIDS).
| Placental transfer | Unknown; molecular weight suggests potential for transfer. |
| Breastfeeding | Not recommended due to possible infant absorption and lack of safety data. |
| Lactation Rating | L5 (Contraindicated) |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to VEETIDSSevere hepatic impairment
| Precautions | Risk of retinal structural abnormalities including retinal thinning and macular hole, Potential for immune responses to AAV capsid proteins, Possible need for systemic corticosteroids to manage ocular inflammation, Not recommended for patients with significant pre-existing retinal damage |
| Food/Dietary | Avoid alcohol consumption as it may potentiate the hypotensive effects of VEETIDS. No other specific food interactions are known. |
| Clinical Pearls |
Loading safety data…
| Teratogenic Risk | First trimester: Category C based on animal studies showing fetal developmental toxicity; avoid unless benefit outweighs risk. Second and third trimesters: Not associated with major teratogenic effects, but may cause fetal respiratory depression and withdrawal syndrome with chronic use. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and respiratory function. Fetal heart rate monitoring during labor; assess neonatal withdrawal signs after chronic use. |
| Fertility Effects | No significant impact on fertility in animal studies; delayed implantation observed at high doses. Human data insufficient. |
| VEETIDS is an intravenous nitrate used for vasodilation in acute heart failure. Onset is rapid within 2 minutes; titrate to effect while monitoring blood pressure closely. Tolerance develops after 24-48 hours of continuous infusion; use intermittent dosing or increase rate if tolerance suspected. Contraindicated in hypertrophic obstructive cardiomyopathy and severe aortic stenosis. Avoid in patients with increased intracranial pressure or cerebral hemorrhage. |
| Patient Advice | This medication is given intravenously to quickly relieve symptoms of heart failure. · Your blood pressure will be monitored closely during infusion. · Report any severe headache, dizziness, or fainting immediately. · Avoid alcohol while on this medication as it may increase side effects. · You may feel lightheaded when standing up; change positions slowly. · Inform your doctor if you are pregnant, breastfeeding, or have low blood pressure. |